| NCT04159701 |
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT04159701 |
Recruiting |
Eli Lilly and Company |
2021-03-03 |
| NCT03580369 |
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines |
https://ClinicalTrials.gov/show/NCT03580369 |
Recruiting |
Novartis |
2021-01-28 |
| NCT03580356 |
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. |
https://ClinicalTrials.gov/show/NCT03580356 |
Recruiting |
Novartis |
2021-04-09 |
| NCT03328897 |
Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT03328897 |
Completed |
Novartis |
2019-07-23 |
| NCT03296358 |
Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department. |
https://ClinicalTrials.gov/show/NCT03296358 |
Completed |
Chulalongkorn University |
2019-10-31 |
| NCT03250143 |
To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria |
https://ClinicalTrials.gov/show/NCT03250143 |
Completed |
Postgraduate Institute of Medical Education and Research |
2017-11-30 |
| NCT03183024 |
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody |
https://ClinicalTrials.gov/show/NCT03183024 |
Completed |
Bernstein Clinical Research Center |
2018-11-06 |
| NCT03137069 |
Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU) |
https://ClinicalTrials.gov/show/NCT03137069 |
Completed |
Genentech, Inc. |
2019-09-27 |
| NCT03111628 |
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) |
https://ClinicalTrials.gov/show/NCT03111628 |
Completed |
Johns Hopkins University |
2020-05-01 |
| NCT02935699 |
Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria |
https://ClinicalTrials.gov/show/NCT02935699 |
Completed |
JDP Therapeutics, Inc. |
2018-04-30 |
| NCT02892682 |
The Role of the Coagulation Pathways in Recurrent Angioedema |
https://ClinicalTrials.gov/show/NCT02892682 |
Recruiting |
University Hospital, Montpellier |
2021-05-31 |
| NCT02824393 |
Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria |
https://ClinicalTrials.gov/show/NCT02824393 |
Completed |
Celal Bayar University |
2018-05-15 |
| NCT02814630 |
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT02814630 |
Completed |
Asthma Inc Clinical Research Center |
2018-11-02 |
| NCT02649218 |
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients |
https://ClinicalTrials.gov/show/NCT02649218 |
Completed |
Novartis |
2019-05-02 |
| NCT02576041 |
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria |
https://ClinicalTrials.gov/show/NCT02576041 |
Completed |
Menarini International Operations Luxembourg SA |
2015-12-31 |
| NCT02565680 |
Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency |
https://ClinicalTrials.gov/show/NCT02565680 |
Completed |
University Hospital, Toulouse |
2014-02-28 |
| NCT02550106 |
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment |
https://ClinicalTrials.gov/show/NCT02550106 |
Completed |
Novartis |
2016-01-11 |
| NCT02477332 |
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU |
https://ClinicalTrials.gov/show/NCT02477332 |
Completed |
Novartis |
2016-11-02 |
| NCT02424799 |
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 |
https://ClinicalTrials.gov/show/NCT02424799 |
Completed |
GlaxoSmithKline |
2017-11-10 |
| NCT02392624 |
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT02392624 |
Completed |
Genentech, Inc. |
2017-03-09 |
| NCT02372604 |
Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT02372604 |
Completed |
Hospices Civils de Lyon |
2016-12-31 |
| NCT02329223 |
Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients |
https://ClinicalTrials.gov/show/NCT02329223 |
Completed |
Novartis |
2015-12-31 |
| NCT02262130 |
Omalizumab in Severe and Refractory Solar Urticaria |
https://ClinicalTrials.gov/show/NCT02262130 |
Completed |
Centre Hospitalier Universitaire de Besancon |
2015-09-29 |
| NCT02213367 |
Bilastine Updosing in Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT02213367 |
Completed |
Charite University, Berlin, Germany |
2016-03-31 |
| NCT02171416 |
Cold Contact Urticaria Treatment With Rilonacept |
https://ClinicalTrials.gov/show/NCT02171416 |
Completed |
Charite University, Berlin, Germany |
2018-02-28 |
| NCT02169115 |
Urticaria Facticia Treatment With Omalizumab (UFO) |
https://ClinicalTrials.gov/show/NCT02169115 |
Completed |
Charite University, Berlin, Germany |
2014-12-31 |
| NCT02161562 |
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients |
https://ClinicalTrials.gov/show/NCT02161562 |
Completed |
Novartis |
2016-11-03 |
| NCT01292473 |
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) |
https://ClinicalTrials.gov/show/NCT01292473 |
Completed |
Genentech, Inc. |
2012-06-30 |
| NCT01287117 |
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
https://ClinicalTrials.gov/show/NCT01287117 |
Completed |
Genentech, Inc. |
2012-10-31 |
| NCT01271075 |
Bilastine Updosing - Characterization of Underlying Mechanisms |
https://ClinicalTrials.gov/show/NCT01271075 |
Completed |
Charite University, Berlin, Germany |
2011-08-31 |
| NCT02023164 |
Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction. |
https://ClinicalTrials.gov/show/NCT02023164 |
Completed |
JDP Therapeutics, Inc. |
2014-12-31 |
| NCT02045524 |
A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers |
https://ClinicalTrials.gov/show/NCT02045524 |
Completed |
JDP Therapeutics, Inc. |
2011-09-30 |
| NCT02031679 |
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines |
https://ClinicalTrials.gov/show/NCT02031679 |
Completed |
Johns Hopkins University |
2016-01-31 |
| NCT02012387 |
Efficacy Study of Omalizumab in Cholinergic Urticaria |
https://ClinicalTrials.gov/show/NCT02012387 |
Completed |
Clinica Universidad de Navarra, Universidad de Navarra |
2016-09-30 |
| NCT01987947 |
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT01987947 |
Completed |
Genentech, Inc. |
2014-10-31 |
| NCT01940393 |
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria |
https://ClinicalTrials.gov/show/NCT01940393 |
Completed |
Grupo de AlergologÃa ClÃnica y Experimental |
2013-12-31 |
| NCT01916967 |
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) |
https://ClinicalTrials.gov/show/NCT01916967 |
Completed |
Merck Sharp & Dohme Corp. |
2014-02-28 |
| NCT01897428 |
PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg |
https://ClinicalTrials.gov/show/NCT01897428 |
Completed |
Korea University Anam Hospital |
2011-05-31 |
| NCT01803763 |
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients |
https://ClinicalTrials.gov/show/NCT01803763 |
Completed |
University Hospital Inselspital, Berne |
2014-03-31 |
| NCT01723072 |
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy |
https://ClinicalTrials.gov/show/NCT01723072 |
Completed |
Novartis |
2014-05-31 |
| NCT01715740 |
Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT01715740 |
Completed |
Chang Gung Memorial Hospital |
2015-08-31 |
| NCT01713725 |
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT01713725 |
Completed |
Clinica Universidad de Navarra, Universidad de Navarra |
2016-02-29 |
| NCT01701583 |
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT01701583 |
Completed |
University of Colorado, Denver |
2016-04-30 |
| NCT01605487 |
Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria |
https://ClinicalTrials.gov/show/NCT01605487 |
Completed |
Charite University, Berlin, Germany |
2013-09-30 |
| NCT01599637 |
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment |
https://ClinicalTrials.gov/show/NCT01599637 |
Completed |
Novartis |
2013-09-30 |
| NCT01586091 |
Safety Study of Levocetirizine and Fexofenadine |
https://ClinicalTrials.gov/show/NCT01586091 |
Completed |
Charite University, Berlin, Germany |
2011-11-30 |
| NCT01580592 |
Cold Urticaria Treatment With Xolair |
https://ClinicalTrials.gov/show/NCT01580592 |
Completed |
Charite University, Berlin, Germany |
2014-12-31 |
| NCT02024152 |
Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg |
https://ClinicalTrials.gov/show/NCT02024152 |
Completed |
JDP Therapeutics, Inc. |
2011-07-31 |
| NCT01444196 |
Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria |
https://ClinicalTrials.gov/show/NCT01444196 |
Completed |
Charite University, Berlin, Germany |
2010-04-30 |
| NCT01371877 |
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment |
https://ClinicalTrials.gov/show/NCT01371877 |
Completed |
University of Nebraska |
2013-09-30 |
| NCT01360658 |
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria |
https://ClinicalTrials.gov/show/NCT01360658 |
Completed |
Centre Hospitalier Universitaire de Besancon |
2013-06-30 |
| NCT04439955 |
Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients |
https://ClinicalTrials.gov/show/NCT04439955 |
Recruiting |
Stero Biotechs Ltd. |
2020-12-30 |
| NCT04210843 |
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab |
https://ClinicalTrials.gov/show/NCT04210843 |
Recruiting |
Novartis |
2022-02-07 |
| NCT04210323 |
Shotblocker® Use in Subcutaneous Injection |
https://ClinicalTrials.gov/show/NCT04210323 |
Completed |
Saglik Bilimleri Universitesi |
2018-06-05 |
| NCT03991845 |
A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT03991845 |
Enrolling by invitation |
Postgraduate Institute of Medical Education and Research |
2019-11-27 |
| NCT03926611 |
Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines |
https://ClinicalTrials.gov/show/NCT03926611 |
Recruiting |
Novartis |
2020-08-17 |
| NCT03907878 |
A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines |
https://ClinicalTrials.gov/show/NCT03907878 |
Recruiting |
Novartis |
2021-10-18 |
| NCT03858634 |
A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases |
https://ClinicalTrials.gov/show/NCT03858634 |
Active, not recruiting |
Kiniksa Pharmaceuticals, Ltd. |
2020-06-30 |
| NCT03789422 |
Tranexamic Acid and Spontaneous Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT03789422 |
Recruiting |
University Hospital, Grenoble |
2021-01-31 |
| NCT03749148 |
Cholinergic Urticaria - Efficacy of Dupilumab |
https://ClinicalTrials.gov/show/NCT03749148 |
Recruiting |
Charite University, Berlin, Germany |
2020-10-31 |
| NCT03749135 |
Dupilumab in Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT03749135 |
Recruiting |
Charite University, Berlin, Germany |
2020-10-31 |
| NCT03693625 |
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study |
https://ClinicalTrials.gov/show/NCT03693625 |
Completed |
Genentech, Inc. |
2019-10-23 |
| NCT03632291 |
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients |
https://ClinicalTrials.gov/show/NCT03632291 |
Recruiting |
United BioPharma |
2021-12-31 |
| NCT03545464 |
COrticosteroids in acUte uRticAria in emerGency dEpartment |
https://ClinicalTrials.gov/show/NCT03545464 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-11-15 |
| NCT03494881 |
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT03494881 |
Recruiting |
Mayo Clinic |
2021-03-15 |
| NCT03437278 |
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) |
https://ClinicalTrials.gov/show/NCT03437278 |
Recruiting |
Novartis |
2021-02-26 |
| NCT03436797 |
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT03436797 |
Completed |
Allakos, Inc. |
2018-11-21 |
| NCT01264939 |
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists |
https://ClinicalTrials.gov/show/NCT01264939 |
Completed |
Genentech, Inc. |
2012-11-30 |
| NCT01250652 |
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses |
https://ClinicalTrials.gov/show/NCT01250652 |
Completed |
Association Asthma, Bulgaria |
2013-02-28 |
| NCT01170936 |
Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses |
https://ClinicalTrials.gov/show/NCT01170936 |
Completed |
Charite University, Berlin, Germany |
2011-09-30 |
| NCT01081574 |
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) |
https://ClinicalTrials.gov/show/NCT01081574 |
Completed |
Faes Farma, S.A. |
2012-06-30 |
| NCT00886795 |
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy |
https://ClinicalTrials.gov/show/NCT00886795 |
Completed |
Johns Hopkins University |
2013-03-31 |
| NCT00866788 |
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) |
https://ClinicalTrials.gov/show/NCT00866788 |
Completed |
Genentech, Inc. |
2010-01-31 |
| NCT00859534 |
Phase II Solar Urticaria (SU) Pilot Study |
https://ClinicalTrials.gov/show/NCT00859534 |
Completed |
Clinuvel Pharmaceuticals Limited |
2009-06-30 |
| NCT04180488 |
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab |
https://ClinicalTrials.gov/show/NCT04180488 |
Recruiting |
Sanofi |
2021-07-31 |
| NCT04109313 |
Open-label, Multicenter, Extension Study to Evaluate Long-term Safety and Tolerability of LOU064 in Subjects With CSU |
https://ClinicalTrials.gov/show/NCT04109313 |
Recruiting |
Novartis |
2020-05-12 |
| NCT01111136 |
Stress Intervention for Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT01111136 |
Completed |
University of Mississippi Medical Center |
2010-07-31 |
| NCT00783354 |
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) |
https://ClinicalTrials.gov/show/NCT00783354 |
Completed |
Merck Sharp & Dohme Corp. |
2004-02-01 |
| NCT00757562 |
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) |
https://ClinicalTrials.gov/show/NCT00757562 |
Completed |
Merck Sharp & Dohme Corp. |
2003-10-01 |
| NCT00751218 |
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) |
https://ClinicalTrials.gov/show/NCT00751218 |
Completed |
Merck Sharp & Dohme Corp. |
2005-05-24 |
| NCT00628108 |
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months |
https://ClinicalTrials.gov/show/NCT00628108 |
Completed |
UCB Pharma |
2008-09-30 |
| NCT00619801 |
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin |
https://ClinicalTrials.gov/show/NCT00619801 |
Completed |
UCB Pharma |
2008-07-31 |
| NCT00600847 |
A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions |
https://ClinicalTrials.gov/show/NCT00600847 |
Completed |
Charite University, Berlin, Germany |
2007-11-30 |
| NCT00598611 |
Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) |
https://ClinicalTrials.gov/show/NCT00598611 |
Completed |
Charite University, Berlin, Germany |
2009-08-31 |
| NCT00536380 |
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) |
https://ClinicalTrials.gov/show/NCT00536380 |
Completed |
Merck Sharp & Dohme Corp. |
2009-04-30 |
| NCT00525382 |
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT00525382 |
Completed |
UCB Pharma |
2004-03-31 |
| NCT00483496 |
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU) |
https://ClinicalTrials.gov/show/NCT00483496 |
Completed |
Orfagen |
2008-04-30 |
| NCT00421109 |
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT00421109 |
Completed |
Faes Farma, S.A. |
2007-07-31 |
| NCT00385372 |
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT00385372 |
Completed |
University Hospital Muenster |
2007-01-31 |
| NCT00368823 |
A Trial of Point of Care Information in Ambulatory Pediatrics |
https://ClinicalTrials.gov/show/NCT00368823 |
Completed |
University of Washington |
NA |
| NCT00264303 |
CUTE (Chronic Urticaria Treatment Evaluation) |
https://ClinicalTrials.gov/show/NCT00264303 |
Completed |
UCB Pharma |
2007-01-31 |
| NCT00214851 |
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria |
https://ClinicalTrials.gov/show/NCT00214851 |
Completed |
Nova Scotia Health Authority |
2005-12-31 |
| NCT01960283 |
Methotrexate in the Treatment of Chronic Idiopathic Urticaria |
https://ClinicalTrials.gov/show/NCT01960283 |
Completed |
University Hospital, Tours |
2016-03-31 |
| NCT00130234 |
Effect of Anti-IgE in Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT00130234 |
Completed |
Johns Hopkins University |
2007-09-30 |
| NCT00795522 |
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) |
https://ClinicalTrials.gov/show/NCT00795522 |
Completed |
Merck Sharp & Dohme Corp. |
2005-02-28 |
| NCT00795158 |
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) |
https://ClinicalTrials.gov/show/NCT00795158 |
Completed |
Merck Sharp & Dohme Corp. |
2004-01-31 |
| NCT00481676 |
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT00481676 |
Completed |
Novartis |
2009-04-30 |
| NCT00288704 |
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) |
https://ClinicalTrials.gov/show/NCT00288704 |
Completed |
Regeneron Pharmaceuticals |
2008-06-30 |